Canakinumab is a human anti-IL-1β monoclonal antibody approved by FDA for cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor receptor-associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), familial Mediterranean fever (FMF), and Still's disease. Here, IL1B is linked to familial Mediterranean fever.